Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploration of poly (ADP-ribose) polymerase inhibitor resistance in the treatment of BRCA1/2-mutated cancer.

Genes, chromosomes & cancer - 1 May 2024

Wu Shuyi, Yao Xuanjie, Sun Weiwei, Jiang Kaitao, Hao Jie

Abstract excerpt

Breast cancer susceptibility 1/2 (BRCA1/2) genes play a crucial role in DNA damage repair, yet mutations in these genes increase the susceptibility to tumorigenesis. Exploiting the synthetic lethality mechanism between BRCA1/2 mutations and poly(ADP-ribose) polymerase (PARP) inhibition has led to the development and clinical approval of PARP inhibitor (PARPi), representing a milestone in targeted therapy for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Drug Resistance, Neoplasm

Share to Mutation

Share to Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 38747337
DOI: 10.1002/gcc.23243

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploration of poly (ADP-ribose) polymerase inhibitor resistance in the treatment of BRCA1/2-mutated cancer.PMID 38747337Read ↗

BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethalitySemantic proximity Read ↗

New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.Semantic proximity Read ↗

‘Where is my gap’: mechanisms underpinning PARP inhibitor sensitivity in cancerSemantic proximity Read ↗

Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatmentSemantic proximity Read ↗

PARP Inhibitors in Breast and Ovarian CancerSemantic proximity Read ↗

PARPi, BRCA, and gaps: controversies and future researchSemantic proximity Read ↗

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) InhibitorsSemantic proximity Read ↗

Mechanisms of resistance to therapies targeting BRCA-mutant cancers.Semantic proximity Read ↗

Crosstalk of DNA double‐strand break repair pathways in poly(ADP‐ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2‐mutated cancerSemantic proximity Read ↗

Strategies for the prevention or reversal of PARP inhibitor resistance.Semantic proximity Read ↗

PARP inhibitor resistance: the underlying mechanisms and clinical implicationsSemantic proximity Read ↗

Chemical inhibition of RPA gap protection sensitizes BRCA1-deficient cancers to PARP inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.